What is the recommended management for a patient with confirmed arrhythmogenic right‑ventricular dysplasia (ARVD) who has experienced an unexplained syncopal episode?

ICD Implantation for ARVD with Unexplained Syncope

An ICD should be implanted in patients with confirmed ARVD who have experienced unexplained syncope, as this represents a Class IIa indication for prevention of sudden cardiac death. 1

Primary Recommendation

The ACC/AHA/ESC guidelines explicitly state that ICD implantation can be effective for prevention of sudden cardiac death in patients with ARVC with undiagnosed syncope when VT or VF has not been excluded as the cause of syncope 1. This is a Class IIa recommendation with Level of Evidence C, meaning it is reasonable and should be considered in most cases.

Clinical Context and Risk Stratification

Syncope in ARVD carries significant prognostic weight:

• Sudden cardiac death is frequently the first manifestation of ARVD, occurring in over 20% of cases 1, 2
• The annual incidence of sudden death in ARVD ranges from 0.08% to 9% 1
• In a multicentre study, patients with unexplained syncope had appropriate ICD interventions at a rate of 15% per year, similar to those with cardiac arrest or hemodynamically compromising VT 3
• Syncope occurs in approximately one-third of ARVD patients referred to tertiary centers 3

Additional High-Risk Features to Assess

When evaluating for ICD implantation, consider these factors that further elevate risk 1:

• Extensive disease with left ventricular involvement
• One or more affected family members with sudden cardiac death
• Young age at presentation
• Extensive right ventricular dysfunction
• Polymorphic VT on monitoring
• Epsilon waves on ECG
• Late potentials on signal-averaged ECG

Complementary Management Strategies

Mandatory Interventions:

• Strict exercise restriction - avoid strenuous or high-intensity sports activities (Class I, Level B) 2
• Chronic optimal medical therapy - typically beta-blockers as first-line
• Referral to an experienced ARVD center (Class I, Level C) 2

Adjunctive Therapies (if ICD not feasible):

• Amiodarone or sotalol can be effective for sustained VT/VF when ICD implantation is not feasible (Class IIa, Level C) 1
• Catheter ablation may be useful as adjunctive therapy for recurrent VT despite optimal antiarrhythmic therapy (Class IIa, Level C) 1

Role of Electrophysiology Testing

EP testing might be useful for risk assessment (Class IIb, Level C) 1, but should not delay ICD implantation in a patient with unexplained syncope. The Canadian guidelines note that EP testing has uncertain prognostic value in ARVD 2.

Critical Pitfalls to Avoid

1. Do not dismiss syncope as benign - unlike idiopathic right ventricular outflow tract VT (which is more common in women and typically benign), ARVD-related syncope carries high arrhythmic risk
2. Do not rely solely on resting ECG - up to 40% may have normal initial ECG, though almost all develop abnormalities within 6 years 2
3. Do not substitute antiarrhythmic drugs or ablation for ICD therapy - these are adjunctive only 2
4. Ensure patient has reasonable life expectancy >1 year with good functional status before ICD implantation 1

Genetic and Family Considerations

• Genetic testing should be considered for families with ARVD for screening and counseling 2
• Most commonly involves desmosomal protein mutations (especially plakophilin-2)
• Family screening is essential given autosomal dominant inheritance pattern

The evidence consistently supports ICD implantation as the primary protective strategy against sudden death in ARVD patients with unexplained syncope, given the high likelihood that ventricular arrhythmias are the underlying cause and the substantial risk of recurrent life-threatening events.